Clear Street Reiterates Buy Rating on Y-mAbs Therapeutics (YMAB) Following Positive Radiopharma R&D Update
Tweet Send to a Friend
Clear Street analyst Bill Maughan reiterated a Buy rating and $17.00 price target on Y-mAbs Therapeutics (NASDAQ: YMAB) with shares ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
